{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:30:34Z","timestamp":1791145834229,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T00:00:00Z","timestamp":1327017600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Refsum's disease is a rare autosomal recessive disorder of fatty acid metabolism. Poorly metabolized phytanic acid accumulates in fatty tissues, including myelin sheaths and internal organs, leading to retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, and renal, cardiac or liver impairment. Dietary restriction of phytanic acid in some cases is not sufficient to prevent acute attacks and stabilize the progressive course. Phytanic acid bound to large low density lipoproteins (LDL) and very low density lipoproteins (VLDL) molecules offers the possibility of extracorporeal elimination by lipid apheresis. We report on the long\u2010term lipid apheresis treatment of four patients with severe Refsum's disease. Retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, anosmia, and sensorineural hearing loss were major symptoms exhibiting a progressive course. Lipid apheresis was performed for 5\u201313 years without severe complications. Maximum levels of phytanic acid before commencing chronic lipid apheresis were &gt;300 mg\/l. During steady state with lipid apheresis, mean phytanic acid before treatments was 87 mg\/l and was reduced to 36 mg\/l. Mean reduction rate was 59% per treatment. In all patients, abnormal motor nerve conduction velocity with signs of chronic denervation improved, morphological and functional stabilization of eye involvement was observed. Lipid apheresis prevented the extension of the disease to previously unaffected organs in three patients. Extracorporeal elimination of lipoprotein\u2010phytanic acid complexes by lipid apheresis represents a pathophysiologically guided therapeutic approach, resulting in long\u2010term improvement or stabilization of overall rehabilitation in patients with progressive Refsum's disease. J. Clin. Apheresis, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/jca.21200","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T17:54:14Z","timestamp":1327082054000},"page":"99-105","source":"Crossref","is-referenced-by-count":33,"title":["Long\u2010term strategies for the treatment of Refsum's disease using therapeutic apheresis"],"prefix":"10.1002","volume":"27","author":[{"given":"D.","family":"Zolotov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kalb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bunia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Heibges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Klingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.18.1971"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200511"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/346093"},{"key":"e_1_2_7_5_2","unstructured":"BaumannN TurpinJC. Orphanet\u2013The Portal for rare diseases and orphan drugs: Refsum disease Orpha number ORPHA773; 2006 last access on 7 December 2011; Available at:http:\/\/www.orpha.net."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2010.03.007"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb01541.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1992.76"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1999)14:4<181::AID-JCA5>3.0.CO;2-Z"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91005-5"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000115788"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1996.tb07051.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005486913371"},{"key":"e_1_2_7_14_2","first-page":"117","article-title":"Cascade filtration in Refsum's disease","volume":"10","author":"Siegmund JB","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-0502(03)00102-2"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139880202501210"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2004.01.008"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.2003.07200.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2006.00315.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.8.1195"},{"key":"e_1_2_7_21_2","first-page":"654","volume-title":"German guidelines for diagnosis and therapy in neurology (Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie)","author":"Diener HC","year":"2008"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005388710197"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)91632-1"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.161059"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.7.614"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.6.671-a"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.7.891"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139880202501210"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00807.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.7.8.1153"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/60.11.1021"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20010075"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M513198200"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M400064-JLR200"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21200","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:18:19Z","timestamp":1697512699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/jca.21200"],"URL":"https:\/\/doi.org\/10.1002\/jca.21200","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}